- Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study
-
Mochizuki T, Yano K, Ikari K, Okazaki K
- KMID: 2537733
- Osteoporos Sarcopenia.
- 2022 Jun;8(2):75-79.
- doi: 10.1016/j.afos.2022.05.001
Objectives: This study aims to examine the 2-year outcomes of zoledronic acid (ZOL) with or without eldecalcitol (ELD) on bone mineral density (BMD) and fracture in Japanese patients with osteoporosis. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial
-
Ni X, Feng J, Jiang Y, Zhang L, Yu W, Wang O, Li M, Xing X, Matsumoto T, Xia W
- KMID: 2518322
- Osteoporos Sarcopenia.
- 2021 Jun;7(2):47-53.
- doi: 10.1016/j.afos.2021.05.003
Objectives: To compare the effect of eldecalcitol and alfacalcidol on skeletal microstructure by highresolution peripheral QCT (HR-pQCT). Methods: This was a substudy of a randomized, double-blind, active comparator trial. Five female... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
-
Suzuki T, Nakamura Y, Kato H
- KMID: 2470598
- Osteoporos Sarcopenia.
- 2019 Dec;5(4):122-127.
- doi: 10.1016/j.afos.2019.11.004
OBJECTIVES: Increasing bone mineral density (BMD) to reduce fracture risk is a primary goal of osteoporosis treatment. This prospective, observational study evaluates the effects of monthly minodronate (MIN; 50 mg)... -
- CITED
-
- Close
- SHARE
-
- Close
- Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
-
Kamimura M, Ikegami S, Mukaiyama , Koiwai H, Nakamura Y, Taguchi A, Kato H
- KMID: 2463607
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):57-61.
- doi: 10.1016/j.afos.2019.06.001
OBJECTIVES: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study
-
Takeuchi Y, Hashimoto , Kakihata H, Nishida Y, Kumagai M, Yamagiwa C
- KMID: 2447618
- Osteoporos Sarcopenia.
- 2019 Mar;5(1):11-18.
- doi: 10.1016/j.afos.2019.02.002
OBJECTIVES: The favorable safety and consistent effectiveness of monthly intravenous (IV) ibandronate injections was demonstrated in a prospective, postmarketing, observational study in Japanese patients with osteoporosis. Here, we present subgroup... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
-
Tanaka M, Nakamura Y, Itoh S, Kato Y
- KMID: 2377001
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):37-44.
- doi: 10.1016/j.afos.2016.12.002
OBJECTIVES: This is an open labeled and retrospective cohort study which compared the effectiveness and safety of ibandronate (IBN) and minodronate (MIN) combined with eldecalcitol (ELD) in primary osteoporosis of... -
- CITED
-
- Close
- SHARE
-
- Close
